Factual and Procedural Background
The Applicant, a multinational pharmaceutical company referred to as "Company A," challenged a decision by the Respondent, "The Health Service Executive" ("The HSE"), to award a contract for the supply of a 6-in-1 vaccine to a Notice Party, "Company B." The contract was intended to supply approximately one million doses over five years starting January 2018, with an additional contingency of 200,000 doses.
Company A's challenge was based on three principal grounds: failure by The HSE to provide adequate reasons for awarding the contract, breach of equal treatment and transparency principles, and manifest error in the evaluation of tenders.
Company A submitted a tender alongside Company B and a third party. The tenders were evaluated by a Procurement Evaluation Group ("PEG") comprising experts in public health and pharmaceutical fields. The PEG conducted a scoring process based on technical, functional, and cost criteria. Company B's tender scored highest overall, largely due to technical and functional criteria, despite Company A scoring better on cost.
Following notification of the award decision, Company A requested detailed reasons for the decision. Correspondence ensued between Company A's attorneys and The HSE's solicitors, with Company A alleging insufficient disclosure of reasons and characteristics of the successful tender. The dispute escalated to judicial review proceedings commenced in February 2018, with Company B joined as a notice party.
Discovery revealed a lack of retained notes from the PEG's evaluation meeting. Company A did not seek to amend its grounds to include this failure. The court emphasized the importance of pleaded grounds and declined to consider new arguments not included in the original statement of grounds.
Legal Issues Presented
- Whether The HSE failed to comply with its duty to provide adequate reasons for awarding the contract to Company B, specifically regarding the characteristics and relative advantages of the successful tender.
- Whether The HSE breached the principles of equal treatment and transparency by failing to formulate and disclose award criteria, sub-criteria, and weightings in a manner that allowed reasonably well-informed and normally diligent tenderers ("RWIND tenderers") to interpret them consistently.
- Whether there was a manifest error in the evaluation of tenders, particularly concerning the scoring of the "Presentation" sub-sub-criterion.
Arguments of the Parties
Applicant's Arguments
- The HSE failed to provide sufficient reasons in the initial notification letter, particularly lacking details on the characteristics and relative advantages of Company B’s tender.
- The principles of equal treatment and transparency were breached due to undisclosed sub-criteria and weightings, notably in relation to side effects, acceptability, and compatibility/interchangeability of vaccines.
- The scoring methodology was flawed, with Company A arguing that its vaccine’s fully liquid presentation was superior and should have resulted in a significantly higher score than awarded.
- The absence and destruction of PEG meeting notes undermined the transparency and reason-giving obligations.
- Company A contended that the HSE’s failure to disclose specific weightings and sub-criteria prevented proper preparation of tenders and infringed procurement regulations.
Respondent's Arguments
- The initial letter of 8 January 2018 constituted the required notification under Regulation 55(1)(b), with detailed reasons provided after Company A’s written request under Regulation 55(2).
- The obligation to provide details of characteristics and relative advantages of the successful tender is triggered only upon written request by the tenderer.
- The HSE complied with its reason-giving obligations by providing sufficient information in subsequent correspondence (22 and 30 January 2018 letters).
- The scoring was conducted in accordance with the published criteria and scoring range, and the evaluation was holistic, applying professional judgment rather than rigid weightings.
- The alleged undisclosed sub-criteria and weightings did not amount to a breach of transparency or equal treatment as they did not alter the published award criteria nor affect tender preparation.
- The PEG’s expertise justified discretion in evaluation, including the scoring of presentation, and the absence of detailed records does not vitiate the evaluation.
Table of Precedents Cited
| Precedent |
Rule or Principle Cited For |
Application by the Court |
| BAM PPP PGGM Infrastructure v. National Treasury Management Agency [2016] IEHC 546 |
Requirement under Regulation 8(4) of the Remedies Regulations to notify contracting authority of alleged infringements before judicial review. |
Confirmed that failure to comply with notification requirements bars pursuing complaints in judicial review. |
| A.P. v. D.P.P [2011] 1 IR 729 |
Requirement for clear and precise pleading of grounds in judicial review proceedings. |
Applied to restrict Company A from advancing arguments not pleaded in its statement of grounds. |
| RPS Consulting Engineers Ltd. v. Kildare County Council [2017] 3 IR 61 |
Standards for adequacy of reasons in procurement decisions, including bespoke statements comparing tenders. |
Used to assess whether HSE provided sufficient reasons to Company A under Regulation 55(2). |
| Connelly v. An Bord Pleanala [2018] IESC 31 |
Rationale for giving reasons: fairness, transparency, and enabling effective judicial review. |
Supported the principle that reasons must enable affected parties to understand decisions and consider challenges. |
| VIP Car Solutions v. Parliament (Case T-89/07) |
Purpose of reason-giving in procurement: awareness of reasons and enabling judicial supervision. |
Referenced in support of obligation to provide reasons. |
| European Dynamics Luxembourg v. OHIM (Case T-299/11) |
Essential procedural requirement to state reasons distinct from correctness of grounds. |
Applied to emphasize procedural duty of contracting authorities. |
| Word Perfect Translation Services Ltd v. Minister for Public Expenditure and Reform (No. 3) [2018] IECA 156 |
No obligation to provide reasons for criteria where unsuccessful tender scored equal or higher than successful tender. |
Applied to limit Company A’s complaint regarding "Presentation" sub-sub-criterion. |
| Lianakis (Case C-532/06) |
Principle of equal treatment and transparency requiring disclosure of all elements and their relative importance. |
Applied to assess whether undisclosed sub-criteria or weightings infringed procurement principles. |
| ATI (Case C-331/04) |
Permits post-submission weighting of pre-published criteria if certain conditions (no alteration, no effect on preparation, no discrimination) are met. |
Used to analyze whether undisclosed weightings were permissible. |
| EUIPO v. European Dynamics Luxembourg SA (Case C-677/15 P) |
Reiterated ATI conditions for applying weightings after tender submission. |
Clarified that undisclosed criteria invalidate awards; weightings may be applied if ATI conditions met. |
| Baxter Healthcare Ltd. v. Health Service Executive [2013] IEHC 413 |
Permits evaluation bodies discretion to apply professional judgment within criteria without rigid tick-box scoring. |
Supported the HSE’s approach to scoring and absence of requirement for detailed weightings. |
| SIAC Construction v. Mayo County Council [2002] 3 IR 148 |
Standard for manifest error in procurement decisions requiring clear, obvious error. |
Applied to assess Company A’s claim of manifest error in scoring presentation. |
| Fresenius Medical Care (Ireland) Ltd. v. Health Service Executive [2013] IEHC 414 |
Judicial review of procurement decisions involves intense scrutiny but defers to expert evaluation unless manifest error. |
Used to frame standard of review for manifest error claim. |
| Somague v. Transport Infrastructure Ireland [2016] IEHC 435 |
Requires rigorous scrutiny of procurement evaluation and whether undisclosed or impermissible criteria affected outcome. |
Referenced in relation to transparency and equal treatment principles. |
Court's Reasoning and Analysis
The court carefully examined the obligations imposed by Regulation 55 of the Procurement Regulations, distinguishing between the notification obligation under Regulation 55(1)(b) and the reason-giving obligation under Regulation 55(2), which is triggered only upon written request by a tenderer. The court accepted the Respondent's submission that the initial letter of 8 January 2018 fulfilled the notification requirement, while the detailed reasons were provided in subsequent correspondence following Company A’s written request.
The court relied on established principles from case law, notably the RPS decision, which requires a contracting authority to provide a bespoke statement of reasons comparing the successful and unsuccessful tenders sufficient to enable the unsuccessful tenderer to understand the basis for rejection and consider judicial review. The court acknowledged that brief or succinct reasons may suffice depending on circumstances.
In assessing the adequacy of reasons provided for the sub-sub-criteria "Side effects and acceptability" and "Compatibility and interchangeability," the court found that the Respondent's detailed letters sufficiently explained why Company B’s tender scored higher, particularly emphasizing Company B’s vaccine being administrable to the total cohort and the absence of thiomersal, which were advantages over Company A’s tender. This information enabled Company A to understand the decision and consider legal challenge.
However, the court identified a manifest failure to provide reasons concerning two other sub-sub-criteria: "Regularity of batch supply and expiry date management" and "Packaging and labelling." The limited commentary provided did not include characteristics or relative advantages of the successful tender. Despite this failure, the court concluded that the point difference was insufficient to affect the overall contract award and quashing the decision would be disproportionate. Instead, the court proposed a declaratory relief and an order requiring The HSE to furnish full reasons within a specified timeframe.
Regarding the principles of equal treatment and transparency, the court analyzed whether undisclosed sub-criteria or weightings were applied. It reviewed the relevant European case law, notably Lianakis, ATI, and EUIPO, which distinguish between the impermissibility of undisclosed criteria and the permissibility of post-submission weighting of pre-published criteria if certain conditions are met.
The court found that the "total cohort" requirement fell within the ambit of "acceptability" as understood by a reasonably well-informed tenderer, supported by Company A’s own tender response and expert affidavits. Thus, it was not an undisclosed sub-criterion. The deductions for side effects and presence of certain substances were considered part of the holistic evaluation and did not amount to undisclosed weightings or criteria violating the ATI conditions. Similarly, the weighting allegedly applied to interchangeability within compatibility and interchangeability was a matter of professional judgment by the PEG and did not breach transparency or equal treatment.
On the manifest error claim concerning the scoring of the "Presentation" sub-sub-criterion, the court applied a deferential standard recognizing the PEG’s expertise and discretion. It found no clear or obvious error warranting judicial interference, noting that the PEG was entitled to assess the practical significance of the vaccine’s presentation and preparation time within the context of clinical practice and existing guidelines.
The court also addressed the lack of retained PEG meeting notes, recognizing it as undesirable but not a standalone ground for quashing the decision, especially as no such claim was pleaded.
Holding and Implications
The court REJECTED the Applicant’s challenge except for the limited failure to provide adequate reasons regarding two sub-sub-criteria.
Specifically, the court found that:
- The HSE complied with its obligations to provide reasons for most evaluation aspects, including side effects, acceptability, and compatibility/interchangeability.
- The principles of equal treatment and transparency were not breached as no undisclosed criteria or impermissible weightings were applied.
- There was no manifest error in the evaluation of the "Presentation" sub-sub-criterion.
- There was a failure to provide adequate reasons concerning "Regularity of batch supply and expiry date management" and "Packaging and labelling," but this failure was not sufficient to justify quashing the contract award.
The court proposed granting declaratory relief for infringement of rights and ordered The HSE to provide full reasons on the two deficient sub-sub-criteria within a timeframe to be fixed. This remedy balances effective judicial protection with proportionality, avoiding unnecessary disruption to the procurement outcome.
No new precedent was established, but the judgment clarifies the application of reason-giving obligations, the scope of transparency and equal treatment principles in public procurement, and the limits of manifest error review in the context of expert evaluation bodies.